🔗 Share this article

As America undertakes unprecedented changes to its vaccine schedules, a particular individual has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who rose to prominence by expressing skepticism about COVID-19 shots during the pandemic and has zeroed in on possible deaths following Covid immunization in her brief time at the US Food and Drug Administration (FDA).

Scheduled Changes to Childhood Immunization Schedule

Agency leaders had intended to reveal major changes to the pediatric vaccination calendar earlier this month, aligning the US with the Danish vaccine program, sources say – a major change that would place the US out of alignment with many the global community with little proof for improved outcomes. The planned update has been pushed back until the next year.

Rather than Vinay Prasad, Høeg is listed to address the audience at the event. She was newly appointed interim head of the FDA’s CDER, the fifth individual to run the office this year.

Consolidating Power at the Agency

The acting appointment could signify a tighter collaboration between the drug and biologics divisions as Dr. Høeg and Dr. Prasad solidify control at the FDA – and it points to a greater focus upon reevaluating already-approved immunizations at the FDA.

Dr. Høeg has repeatedly called for discontinuing specific childhood immunization guidelines in the US so as to align more similar to the Danish model, a nation with universal health coverage and a population roughly the size of the state of Wisconsin.

In her initial public appearances, she has kept her attention on immunizations – usually the responsibility of Prasad, director of the FDA’s CBER – as opposed to pharmaceutical oversight.

Doubts Over Qualifications

Høeg has no obvious experience in medication creation, approval processes or leadership, which has been customary for former leaders of the biologics center. She has worked at the FDA as a top consultant to the agency head and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for running the pharmaceutical oversight division, said Jonathan Howard. “She has not conducted a randomized controlled trial. She lacks experience in running a major agency. She lacks background in pharmaceutical oversight.”

Previous heads of the center would “understand regulatory frameworks and the underlying principles of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that former directors who led CBER have had.”

CDER has an enormous workload at the agency, the former commissioner stated.

“The public just zeroes in on the innovative therapies, but the generic drug division authorizes a multitude of generic medications. There is also a biosimilars program, OTC medication office and more, and every single one need to be managed,” Dr. Woodcock noted. “The responsibility you overlook, that is the part that I always told people is going to come back to haunt you.”

Furthermore, a substantial leadership aspect to the position, which supervises more than 5,000 staff members. “It is a huge administrative position, if you do it right,” the former official added.

Response and Contentious Policies

Regarding concerns about Dr. Høeg's fitness for the role and whether this assignment signifies increased cooperation among FDA leaders on vaccines, a spokesperson responded that the “questions stem from incorrect assumptions”.

“This background aligns with the duties of her role,” the official stated, pointing to the period Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s controversial fast-track approval initiative, a contentious expedited medication authorization process that apparently troubled her former heads. “By what process are these therapies being selected for this fast-track system? Who makes the calls?” Howard questioned. “There is a lot of secrecy occurring at the agency right now.”

In general, he stated, “the agency appears to be shifting towards laxer oversight of all drugs, except for vaccines.”

Established History on Immunizations

With vaccines, Høeg has a more documented, if problematic, past, critics said. She published a analysis using non-validated volunteer-provided data to determine the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who allegedly have altered data to suggest Covid vaccinations are riskier than they are.

Among her “policy goals” for the current federal leadership encompassed revising rules for novel immunizations and ending “unnecessary” vaccines, she remarked post-election on a podcast. At the FDA, Høeg has according to sources suggested excluding teenage boys from getting Covid vaccines.

“She is an complete dogmatist who commences with her conclusions and tailors the evidence to retrofit the evidence in a extremely deceptive, untruthful way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Høeg joined other dissenters, {like|